Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
18 avr. 2024 07h00 HE
|
Ocular Therapeutix, Inc.
46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the...
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
16 avr. 2024 07h00 HE
|
Ocular Therapeutix, Inc.
Nadia K. Waheed, MD, MPH, Appointed Chief Medical Officer; Peter K. Kaiser, MD, to Become Chief Development Officer; Andrea Gibson, PhD, Named Vice President, Medical Collaborations; and Namrata...
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
15 avr. 2024 07h00 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
09 avr. 2024 07h30 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through...
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
06 avr. 2024 10h00 HE
|
Ocular Therapeutix, Inc.
Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with clinically meaningful reductions of 24-30%...
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
26 mars 2024 07h30 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of...
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
11 mars 2024 16h05 HE
|
Ocular Therapeutix, Inc.
Leadership Appointments Move Ocular Towards Being a Leader in Retinal Care Screening Underway in AXPAXLI™ Phase 3 SOL-1 Trial for Wet AMD Topline Clinical Data for AXPAXLI in Diabetic Retinopathy...
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
05 mars 2024 07h30 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life...
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
22 févr. 2024 07h32 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through...
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
22 févr. 2024 07h31 HE
|
Ocular Therapeutix, Inc.
BEDFORD, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq:OCUL) (the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life...